GLP-1/GIP dual target weight loss innovative drug. Jul 26, 2026 View: 104 Leave a message GLP-1 Injections 1.General Specification(in stock) (1)API(Pure powder) (2)Tablet (3)Capsule (4)Injection (5)Liquid Drops 2.Customization: Shaanxi BLOOM Tech Co., Ltd will negotiate individually, OEM/ODM, No brand, for secience researching only. Internal Code:BM-3-094 GLP-1 CAS 87805-34-3 Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand, Canada etc. Manufacturer: BLOOM TECH Xi'an Factory Analysis: HPLC, LC-MS, HNMR Technology support: R&D Dept.-4 Shaanxi BLOOM Tech Co., Ltd provide GLP-1 injections, please refer to the following website for detailed specifications and product information. Hanson Pharmaceutical's GLP-1/GIP dual target weight loss innovative drug, Olepotide, has been accepted for application and marketing for weight loss indications. On June 4, 2026, Hanson Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hanson Pharmaceutical", 03692. HK) announced that the company's innovative drug Olepotide Injection Market Authorization Application (NDA) has been accepted by the National Medical Products Administration (NMPA) of China for long-term weight management in obese or overweight adults. Olepotide is a glucagon like peptide-1 (GLP-1)/glucose dependent insulinotropic polypeptide (GIP) dual receptor agonist independently developed by Hanson Pharmaceuticals. By selectively activating GLP-1/GIP receptors, it regulates metabolic pathways related to appetite control, glucose metabolism, and energy balance, producing biological effects such as sugar control and weight loss. Its administration method is once a week, subcutaneous injection. In March 2026, the first phase III clinical study (HS-20094-301) of olepotide in overweight or obese adult subjects in China achieved its primary endpoint. After 48 weeks of treatment with olepotide, the average weight loss from baseline was as high as 19.3%, and the proportion of subjects who achieved a 25% weight loss was as high as 97.2%. Research has shown that the treatment group with oxaliplatin exhibits excellent gastrointestinal tolerance, with an average nausea incidence rate of<10% and an average vomiting incidence rate of<5%. Compared with the phase III trial data of GLP-1 related dual agonist drugs that have been published, the incidence of gastrointestinal adverse events and treatment discontinuation rate are lower. The dual target CAR-T cell injection of mRNA LNP from Shiyao Group has been approved for clinical use in China. On June 2, 2026, Shiyao Group (1093. HK) announced that its first dual target chimeric antigen receptor (CAR) - T-cell injection (SVS6063 injection) based on mRNA LNP has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is the world's first approved dual target cell therapy product based on mRNA LNP. By expressing CAR that can specifically recognize leukocyte differentiation antigen 19 (CD19) and B-cell maturation antigen (BCMA), it accurately identifies and eliminates CD19 and BCMA positive cells in patients' bodies, thereby achieving therapeutic goals. The synergistic effect of dual targets can eliminate pathogenic cells from the source, fundamentally improve the patient's condition, and solve the pain points that traditional treatments cannot cure and are prone to recurrence. Preclinical studies have shown that this product can significantly kill CD19 and BCMA positive cells, and has good safety and efficacy. The clinical indication approved this time is relapsed and refractory systemic lupus erythematosus. In addition, this product is expected to be used for the treatment of other B cell/plasma cell-mediated autoimmune diseases such as myasthenia gravis (MG), rheumatoid arthritis (RA), and anti neutrophil cytoplasmic antibody (ANCA) - related vasculitis. It can also be extended to relapsed/refractory multiple myeloma (MM), B-cell lymphoma, and other hematological tumors, and has high clinical development value. The approval of the clinical trial of this product is another important achievement of its group's layout in the field of cell therapy, laying a good foundation for the development of cell therapy products including in vivo generated CAR-T. -Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies. On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure). Zilebesiran is a subcutaneous RNAi therapy developed by Alnylam based on its enhanced stable chemical PLUS (ESC+) GaINAc conjugate technology. It reduces angiotensin levels by targeting the synthesis of angiotensinogen (AGT), the most upstream component of the renin angiotensin aldosterone system (RAAS), a classic pathway for blood pressure regulation. Ultimately, it leads to a sustained decrease in blood pressure. In July 2023, Roche and AInylam reached an agreement to obtain the cooperative development and commercialization rights of the drug for a total transaction value of up to $2.8 billion. In September 2025, the two parties launched Zilebesiran's first phase IV clinical trial. ZENISH). This study is a global, randomized, double-blind, placebo-controlled clinical trial (n=11000) aimed at evaluating the effectiveness and safety of Zilebesiran (300mg, subcutaneous injection, once every 6 months) combined with standard treatment (OC) compared to placebo combined with SOC in reducing the incidence of major cardiovascular adverse events (MACE) in hypertensive adult patients with diagnosed cardiovascular disease or poor blood pressure control at high risk of cardiovascular disease. The primary endpoint of the study is the time to the first occurrence of cardiovascular death, non fatal myocardial infarction (MI), non fatal stroke, or heart failure (HF) within 5 years of treatment. 1.9 billion US dollars! Eli Lilly and Ascidian reach a global agreement to develop RNA exon editing drugs. On June 3, 2026, Ascidian Therapeutics announced today that it has reached a global research collaboration and licensing agreement with Ei Lily and Company. Both parties will jointly discover and develop therapies for undisclosed monogenic kidney diseases, and Ei Lily has the right to choose to expand the collaboration to other targets. Ascidian's RNA exon editor can edit multiple complete exons at the kilobase scale to repair genetic instructions that cause diseases. This technology is designed specifically to address large genes or genes with high mutation diversity, expanding the boundaries of gene drugs. According to the terms of the agreement, Eli Lilly will obtain exclusive, target specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets. Ascidian will lead drug discovery and selected preclinical activities, while Eli Lilly will be responsible for additional preclinical research, clinical development, production, and commercialization. Ascidian is eligible for up to $1.9 billion in payments, including prepayments, development and commercialization milestone payments, and tiered royalties based on global sales. Ascidian reserves the right to independently or jointly develop other targets in the field of kidney with other partners. Alnylam and Inceptive have reached a strategic AI collaboration to accelerate the development of RNAi therapy. On June 3, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) and lnceptive Nucleics, a company dedicated to building life science foundation models, announced today that they have signed a strategic partnership agreement aimed at accelerating the development of innovative therapeutic drugs. The total value of the partnership project is up to $2 billion, including a $30 million advance payment (including cash and Inceptive equity subscription). In addition, Inceptive is eligible for additional interim payments based on the achievement of milestones such as preclinical research, regulatory approvals, and commercial sales. This collaboration combines AInvlam's leadership position in the RNAi field with lnceptive's foundational models and AI expertise, aiming to catalyze and accelerate the development of nucleic acid drug design. Innovative focuses on developing models for stem based drugs, such as RNAi therapy pioneered by Alnylam. Alnylam's platform: a research and development engine that has produced six marketed drugs and has over 20 years of proprietary siRNA data support. Inceptive Life Foundation Model: Suitable for A! Models based on sequential drugs, it can generalize and continuously self optimize across different projects. The aim of this collaboration is to model the target mRNA and jointly explore sequence space and novel chemical modifications to enhance efficacy and therapeutic effects, while predicting the optimal therapeutic candidate molecules in preclinical models for further development by AInyiam, thereby promoting advances in SiRNA design. Its goal is to help Alnylam prioritize the screening of the most promising molecules and improve experimental efficiency. No Information Send Inquiry

Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership. Lilly's deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines. Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney diseases - adding another bead to the string of genetic medicine-focused deals Lilly has signed over the past few months. Through this partnership worth up to $1.9bn for Ascidian, the pair will initially look to discover and develop therapies for kidney diseases caused by a singular gene, though Lilly can choose to expand to additional targets if the company so chooses. In exchange for an undisclosed upfront payment and its commitment to potential milestone and tiered royalty payments, Lilly will receive the exclusive, target-specific rights to Ascidian's RNA exon editing technology for certain kidney disease targets, which currently remain undisclosed. As per the deal, Ascidian will take charge of the discovery and some of the preclinical activities associated with any targets identified through the partnership, while Lilly will take the helm for additional preclinical work, as well as clinical R&D, manufacturing and commercialisation. The key driver of these efforts will be Ascidian's RNA-based exon editors, which are designed to correct faulty genes linked to disease at the kilobase scale. According to Ascidian's president and CEO, Michael Ehlers, this approach offers the opportunity to rewrite genes at their source without altering DNA, which he says could "open the door to diseases long out of reach" with current gene and base editing approaches. Ascidian also touts the potential of the RNA exon editing approach in lowering the risks linked to direct DNA editing and gene replacement, while providing a durable response similar to those seen with gene therapies. Lilly's dealmaking spree continues. Lilly's deal with Ascidian is the big pharma company's third this week alone, following its $1.26bn licensing deal with Hanmi Pharm for its glucagon-like peptide 2 (GLP-2) agonist, sonefpeglutide, and its $3bn deal with Haisco Pharmaceutical to develop innovative medicines. While Lilly has been casting the net wide with its dealmaking strategy, the company has heavily invested in genetic medicines over the last year, with the company penning multiple partnerships, licensing deals and acquisitions with biotechs in the space. As the pharma giant waits to see if these approaches will bear fruit, it is also making active efforts to bolster its genetic medicines manufacturing output, having pledged $4.5bn to upgrade its dedicated Indiana-based facility on its Lebanon campus back in May 2026. These hefty investments come as Lilly looks to expand its commercial success by building a diversified pipeline - funded by the capital generated from strong sales of its weight loss portfolio, which continued on its strong growth trajectory in Q1 following a stellar 2025. Outside of the genetic medicines realm, notable Lilly deals from 2026 include its $7.8bn acquisition of sleep drug biotech, Centessa, as well as its $8.8bn pact with Chinese biotech, Innovent, focused on developing new cancer and immune disorder therapies.

Eli Lilly, Ascidian sign $1.9 billion deal to develop kidney-disease treatments. Published on 06/03/2026 at 09:08 am EDT By Katherine Hamilton Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments. Ascidian, a Boston-based biotechnology company, said Wednesday it granted Eli Lilly exclusive, target-specific rights to its RNA-exon-editing technology for undisclosed kidney-disease targets. The RNA-exon editors are capable of altering parts of genetic code to repair genetic instructions that cause disease. Ascidian said it will lead discovery and certain preclinical activities, while Eli Lilly will be responsible for other preclinical work, clinical development, manufacturing and commercialization. Ascidian is eligible to receive up to $1.9 billion, including an upfront payment, development and commercial milestone payments, and tiered royalties on commercial sales worldwide, it said. Ascidian is retaining the right to pursue other targets in kidney disease, it said. Write to Katherine Hamilton at [email protected] (END) Dow Jones Newswires 06-03-26 0907ET (C) Dow Jones - 2026